214 related articles for article (PubMed ID: 19888912)
1. Evaluation of adverse cardiac effects induced by arsenic trioxide, a potent anti-APL drug.
Raghu KG; Yadav GK; Singh R; Prathapan A; Sharma S; Bhadauria S
J Environ Pathol Toxicol Oncol; 2009; 28(3):241-52. PubMed ID: 19888912
[TBL] [Abstract][Full Text] [Related]
2. Prolongation of cardiac repolarization by arsenic trioxide.
Chiang CE; Luk HN; Wang TM; Ding PY
Blood; 2002 Sep; 100(6):2249-52. PubMed ID: 12200393
[TBL] [Abstract][Full Text] [Related]
3. Characterization of cytotoxicity induced by arsenic trioxide (a potent anti-APL drug) in rat cardiac myocytes.
Raghu KG; Cherian OL
J Trace Elem Med Biol; 2009; 23(1):61-8. PubMed ID: 19203718
[TBL] [Abstract][Full Text] [Related]
4. Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and an electrophysiological study in isolated guinea pig papillary muscles.
Yamazaki K; Terada H; Satoh H; Naito K; Takeshita A; Uehara A; Katoh H; Ohnishi K; Hayashi H
Circ J; 2006 Nov; 70(11):1407-14. PubMed ID: 17062962
[TBL] [Abstract][Full Text] [Related]
5. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
Wang QQ; Hua HY; Naranmandura H; Zhu HH
Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440
[TBL] [Abstract][Full Text] [Related]
6. Myocardial toxicity of acute promyelocytic leukaemia drug-arsenic trioxide.
Mathews VV; Paul MV; Abhilash M; Manju A; Abhilash S; Nair RH
Eur Rev Med Pharmacol Sci; 2013 Feb; 17 Suppl 1():34-8. PubMed ID: 23436664
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of Long Non-Coding RNA Kcnq1ot1: An Important Mechanism of Arsenic Trioxide-Induced Long QT Syndrome.
Jiang Y; Du W; Chu Q; Qin Y; Tuguzbaeva G; Wang H; Li A; Li G; Li Y; Chai L; Yue E; Sun X; Wang Z; Pavlov V; Yang B; Bai Y
Cell Physiol Biochem; 2018; 45(1):192-202. PubMed ID: 29339628
[TBL] [Abstract][Full Text] [Related]
8. Molecular targets of arsenic trioxide in malignant cells.
Miller WH
Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide: mechanisms of action.
Davison K; Mann KK; Miller WH
Semin Hematol; 2002 Apr; 39(2 Suppl 1):3-7. PubMed ID: 12012315
[TBL] [Abstract][Full Text] [Related]
10. Direct effects of arsenic trioxide on action potentials in isolated cardiac tissues: importance of the choice of species, type of cardiac tissue and perfusion time.
Lu HR; Vlaminckx E; Cools F; Gallacher DJ
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):135-44. PubMed ID: 22445855
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide induces cardiac fibroblast apoptosis in vitro and in vivo by up-regulating TGF-β1 expression.
Li C; Qu X; Xu W; Qu N; Mei L; Liu Y; Wang X; Yu X; Liu Z; Nie D; Liu Y; Yan J; Yang B; Lu Y; Chu W
Toxicol Lett; 2013 Jun; 219(3):223-30. PubMed ID: 23542815
[TBL] [Abstract][Full Text] [Related]
12. Potential of natural products in combination with arsenic trioxide: Investigating cardioprotective effects and mechanisms.
Wang J; Liu YM; Hu J; Chen C
Biomed Pharmacother; 2023 Jun; 162():114464. PubMed ID: 37060657
[TBL] [Abstract][Full Text] [Related]
13. Arsenic-induced interstitial myocardial fibrosis reveals a new insight into drug-induced long QT syndrome.
Chu W; Li C; Qu X; Zhao D; Wang X; Yu X; Cai F; Liang H; Zhang Y; Zhao X; Li B; Qiao G; Dong D; Lu Y; Du Z; Yang B
Cardiovasc Res; 2012 Oct; 96(1):90-8. PubMed ID: 22853924
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide induces accumulation of cytotoxic levels of ceramide in acute promyelocytic leukemia and adult T-cell leukemia/lymphoma cells through de novo ceramide synthesis and inhibition of glucosylceramide synthase activity.
Dbaibo GS; Kfoury Y; Darwiche N; Panjarian S; Kozhaya L; Nasr R; Abdallah M; Hermine O; El-Sabban M; de Thé H; Bazarbachi A
Haematologica; 2007 Jun; 92(6):753-62. PubMed ID: 17550847
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY; Yang CH; Chen YC
Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of α-lipoic acid against arsenic trioxide-induced acute cardiac toxicity in rats.
Kumazaki M; Ando H; Sasaki A; Koshimizu TA; Ushijima K; Hosohata K; Oshima Y; Fujimura A
J Pharmacol Sci; 2011; 115(2):244-8. PubMed ID: 21282932
[TBL] [Abstract][Full Text] [Related]
17. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin F; Roncolato F; Ho WK
Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
[TBL] [Abstract][Full Text] [Related]
18. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies.
Chou WC; Dang CV
Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884
[TBL] [Abstract][Full Text] [Related]
19. Torsemide increases arsenic concentrations by inhibition of multidrug resistance protein 4 in arsenic trioxide treated acute promyelocytic leukemia patients.
Lv J; Wu M; Pang C; Duan R; Zhang H; Tian S; Yang H; Hai X
Biomed Pharmacother; 2023 Jul; 163():114858. PubMed ID: 37172335
[TBL] [Abstract][Full Text] [Related]
20. Omega-3 Fatty Acid Protects Against Arsenic Trioxide-Induced Cardiotoxicity In Vitro and In Vivo.
Varghese MV; Abhilash M; Paul MV; Alex M; Nair RH
Cardiovasc Toxicol; 2017 Apr; 17(2):109-119. PubMed ID: 26886836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
